Eileen Gu's  Instablog

In 2008, affected by the law of the real estate market, the declining international economic trends and the domestic macro economy, the sales achievements of Chinese real estate enterprisers showed the dropping tendency, however, the top 100 real estate enterprises showed the general outperform tendency. In 2008, the sales amounts of the commercial buildings reached 2.4071 trillion Yuan, down by 19.47% YOY; at the same time, the sales of the top 100 enterprises amounted to 524.4 billion Yuan, only down by 3.93% YOY, 15 percentage points higher than the industrial average level, in which the sales amounts of 33 top-100 enterprises kept growing and the average growth rate was 32.72%. The sales amounts of Vanke, Poly, Wanda and Greentown all exceeded millions Yuan, in which the sales amounts of Vanke went beyond 40 billion Yuan; Poly first broke through the sales amounts of 20 billion Yuan; the growth rate of the sales amounts of China Overseas Land & Investment Ltd, Gemdale and Longfor etc all passed 10 percentage points. It is predicted that Chinese top 100 ral estate enterprises will still lead the development of the real estate industry in 2009.

More information can be obtained in this report:

- Company Profiles of Chinese Top 100 Real Estate Enterprises

- Operations of Chinese Top 100 Real Estate Enterprises

- Development Strategies of Chinese Top 100 Real Estate Enterprises

- Present Development Situation of Chinese Real Estate Industry

To get more details, please visit www.cri-report.com/business/124-research...

(CRI-report) -Thrombosis refers to the formation of local blood clots. Among it, artery thrombosis can cause myocardial infarction, stroke, acute coronary syndrome, peripheral arterial diseases, etc.; venous thrombosis can cause pulmonary embolism. Arteriovenous thrombosis is the primary reason for incidence and death of cardiovascular diseases, which is also one of the important causes for death of cancer patients.

Nowadays, cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) are severely threatening the life and health of the elderly worldwide. Cardiac-cerebral thrombotic diseases are called as the No.1 killer of the life and health of human beings currently. Cardiac-cerebral thrombotic diseases are characterized by high incidence rate, mortality rate and disability rate as well as suddenness. Since the reform and opening up, because of the continuous improvement in people's living standards as well as the rise in aging trend, the incidence rate of cardiac-cerebral thrombotic diseases continuously rises in China. According to statistics, the proportion of people dying from cardiac-cerebral thrombotic diseases already exceeds 70% in the dead aged above 60 in China's large cities. At present, the morbidity and mortality rates of cardiac-cerebral thrombotic diseases in China are higher than that in some developed countries. In addition, patients tend to be increasingly young.

It is reported that at present, over 7 million patients suffer from acute cardiac-cerebral thrombotic diseases (stroke and myocardial infarction) in China annually. Among them, nearly half of the patients die; in survival patients, nearly two-thirds of them are maimed or completely lose self-care ability of daily living. Cardiac-cerebral thrombotic diseases cause not only pain to patients but also huge economic burdens to their families.

Full report: www.cri-report.com/drug/9847-research-re...

Antithrombotic drugs are used for the prevention and treatment of thromboembolic diseases, with the emphasis on prevention. Clinically, they are mainly used for the treatment and prevention of acute myocardial infarction and stroke embolism, which can reduce rates of re-infarction and mortality; they can be used for the prevention of heart valve replacement surgery postoperative thrombosis and the treatment of occlusive peripheral vascular diseases, intermittent claudication, unstable angina pectoris, etc. At present, the fast-growing indication is the prevention of deep vein thrombosis after orthopedic surgeries (such as knee and hip replacement surgeries as well as abdominal surgery).

Antithrombotic drugs are divided into anticoagulants, anti-platelet aggregation drugs and thrombolytic drugs. The overall market size of China's antithrombotic drugs is small, but it rapidly grows in recent years. The market growth rate was consecutively over 20% from 2006 to 2012. The market size of hospital-use antithrombotic drugs reaches CNY 9.92 billion in 2012, with an increase of 21.9% YOY.

As the population further aging in China, on one hand, the incidence rate of vascular embolic diseases rises year by year; on the other hand, surgeries such as the interventional treatment of cardiovascular and cerebrovascular rapidly develop. The synchronous follow-up of anti-freezing, anti-platelet and lowering the blood lipid treatment after the stent surgery, promotes the capacity expansion of China's antithrombotic drug market. The market size of China's hospital-use antithrombotic drugs is expected to be over CNY 20 billion in 2017.

More following information can be acquired through this report:

-Incidence of Thrombosis in China

- Market Situation of China's Antithrombotic Drugs in Hospitals

-China's Major Antithrombotic Drug Manufacturers and Competition

-Development Trend of Antithrombotic Drugs in China

- Following people are recommended to buy this report:

- Antithrombotic Drug Manufacturers

- Pharmaceutical Trade Enterprises

-Hospitals

- Investors/Research Institutions Focusing on Pharmaceutical Industry

Full report: www.cri-report.com/drug/9847-research-re...

(CRI-report) -In recent years, the market size of China's medical services continuously expands, but whole medical services are on the rather low level. The rich and foreigners in China attach importance to quality and privacy of medical services and they are unwilling to accept the noisy and crowded hospital environment and inferior service attitudes of public hospitals. Insensitive to prices or enjoying high-end medical insurances, they can afford high medical expenses.

In current China, high-end medical services are carried out through three primary channels: high-end general hospitals (clinics), high-end specialized hospitals (clinics) and high-end service departments of public hospitals. In the general hospital industry, there are hundreds of high-end medical institutions in economically-developed cities such as Shanghai and Beijing. Among them, there are some hospitals sharing doctors of public hospitals and high-end service departments managed by foreign-funded medical institutions under entrustment of public hospitals. The thresholds of high-end specialized hospitals are rather low, especially rapidly-developing specialized hospitals for eyes, dentistry and women and children in China. The growth rate of China's high-end medical market size is rapid. Meanwhile, problems such as the high flow rate of doctors and insufficient supply exist. For example, the current market capacity of Shanghai's high-end medical services is over CNY 10 billion, but the actual revenue is less than CNY 4 billion annually. Many effective demands remain to be satisfied.

Multiple high-end services of public hospitals early develop in China- including official healthcare, international services, general special medical treatment, etc. However, doctors are shared by high-end and common medical treatments in several public hospitals. Aiming at special crowds, the high fee, prior appointment and preferential treatment cause dissatisfaction of common patients. Moreover, high fees, poor services and other problems arouse controversy. In the long term, the development prospect of high-end services in public hospitals is bleak.

In China, the convenient service and comfortable environment are main reasons which initially attract patients to head for high-end medical institutions. Because barriers to entry of dental, eye, physical examination, gynaecology and other fields are rather low and the high-end specialized medical treatment is easier to create characteristics through equipment, technologies and services, China's high-end medical services are concentrated in these fields. However, investments in general hospitals are high and their competitiveness is hard to be exceeded compared with common hospitals, so high-end general hospitals are scarce in current China.

Compared with eyes, dentistry, physical examination, gynaecology, etc., there are a few high-end specialized hospitals in China's tumors, cardiovascular diseases, rehabilitation medical treatment and other fields, and the market demand is on the continuous rise.

Full report: www.cri-report.com/medical/9846-research...

With the expansion of China's high-end medical service market, some foreign-funded medical institutions accelerate the expansion in China. Meanwhile, the high-end trend of some private medical institutions is evident. As for industrial policies, the policy of "doctors' practices in many places" and easing policies of Chinese government for investment in medical institutions of foreign capital, etc. are beneficial to the development of the industry.

On the whole, service targets and contents of China's high-end medical treatment are gradually diversified. Target customers of China's high-end medical institutions gradually shift from the major officials and foreigners working in China to domestic non-official high-income groups. With the development of China's economy, there are hundreds of millions of people with the annual household income of over CNY 100 thousand, which boosts the development of China's high-end medical industry.

Malignant tumors, heart diseases and cerebrovascular diseases become the top 3 diseases causing the death of China's urban citizens. These diseases need to be patiently treated in the long term. It is obvious that the common medical industry monopolized by public hospitals is difficult to effectively meet the demand of medium and high-income patients. Therefore, the prospect of high-end medical services is promising. Although the whole market size of China's high-end medical treatment is less than CNY 100 billion in 2012, the figure is predicted to surmount CNY 200 billion by 2017. In the coming years, the annual growth rate of market size of China's high-end medical treatment will be far higher than that of the whole medical market.

More following information can be acquired through this report:

- Current Supply and Demand of China's High-end Medical Services

-High-end Medical Services in Dental, Eye, Physical Examination and Other Fields

-Competition in China's High-end Medical Industry

-Introduction of Major High-end Medical Enterprises in China

-Development Trends and Investment Opportunities of China's High-end Medical Industry

Following people are recommended to buy this report:

-High-end Medical Institution Practitioners

-Medical Equipment Production and Trade Enterprises

-Investors and Research Institutions Focusing on High-end Medical Treatment Industry

Full report: www.cri-report.com/medical/9846-research...